CA2628015C - Fixed ratio drug combination treatments for solid tumors - Google Patents

Fixed ratio drug combination treatments for solid tumors Download PDF

Info

Publication number
CA2628015C
CA2628015C CA2628015A CA2628015A CA2628015C CA 2628015 C CA2628015 C CA 2628015C CA 2628015 A CA2628015 A CA 2628015A CA 2628015 A CA2628015 A CA 2628015A CA 2628015 C CA2628015 C CA 2628015C
Authority
CA
Canada
Prior art keywords
floxuridine
irinotecan
tumor
cancer
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2628015A
Other languages
English (en)
French (fr)
Other versions
CA2628015A1 (en
Inventor
Lawrence Mayer
Christine Swenson
Andrew Janoff
John Redman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of CA2628015A1 publication Critical patent/CA2628015A1/en
Application granted granted Critical
Publication of CA2628015C publication Critical patent/CA2628015C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2628015A 2005-10-25 2006-10-25 Fixed ratio drug combination treatments for solid tumors Active CA2628015C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73019905P 2005-10-25 2005-10-25
US60/730,199 2005-10-25
US75922506P 2006-01-12 2006-01-12
US60/759,225 2006-01-12
PCT/US2006/041832 WO2007050784A2 (en) 2005-10-25 2006-10-25 Fixed ratio drug combination treatments for solid tumors

Publications (2)

Publication Number Publication Date
CA2628015A1 CA2628015A1 (en) 2007-05-03
CA2628015C true CA2628015C (en) 2016-02-23

Family

ID=37882130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2628015A Active CA2628015C (en) 2005-10-25 2006-10-25 Fixed ratio drug combination treatments for solid tumors

Country Status (7)

Country Link
US (2) US7842676B2 (https=)
EP (1) EP1951239A2 (https=)
JP (1) JP5687411B2 (https=)
AU (1) AU2006306108B2 (https=)
CA (1) CA2628015C (https=)
IL (1) IL191040A (https=)
WO (1) WO2007050784A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2012088414A1 (en) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
SI2768484T1 (sl) 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP3028933A1 (en) * 2014-12-05 2016-06-08 Öhlins Racing Ab Spring unit
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
CN107281102A (zh) * 2016-04-11 2017-10-24 江苏竞诺择生物医药科技有限公司 一种用于结直肠肿瘤治疗的药物微粒组合物
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
MX2021006557A (es) 2018-12-04 2021-09-08 Der Yang Tien Estereocomplejos para la administración de agentes anticancerígenos.
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4704807A1 (en) 2023-05-03 2026-03-11 IOX Therapeutics Limited Inkt cell modulator liposomal compositions and methods of use
WO2025085591A1 (en) * 2023-10-17 2025-04-24 Jnd Therapeutics, Inc. Low dosing regimens of floxuridine and methods of treatment of cancer using floxuridine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272768T3 (es) * 2001-10-03 2007-05-01 Celator Pharmaceuticals Inc Composiciones para la administracion de combinaciones de farmacos.
US20040265368A1 (en) * 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines

Also Published As

Publication number Publication date
EP1951239A2 (en) 2008-08-06
AU2006306108A1 (en) 2007-05-03
US20100189771A1 (en) 2010-07-29
CA2628015A1 (en) 2007-05-03
JP5687411B2 (ja) 2015-03-18
WO2007050784A3 (en) 2007-06-14
IL191040A0 (en) 2009-08-03
US7842676B2 (en) 2010-11-30
JP2009513662A (ja) 2009-04-02
AU2006306108B2 (en) 2012-10-04
WO2007050784A2 (en) 2007-05-03
IL191040A (en) 2012-06-28
US20090023680A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
CA2628015C (en) Fixed ratio drug combination treatments for solid tumors
EP2344161B1 (en) Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
JP6857210B2 (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
Ardizzoni et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
AU2017354903B2 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
KR101434009B1 (ko) 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
WO2009099649A1 (en) Use of picoplatin and bevacizumab to treat colorectal cancer
IL257149B1 (en) Methods for treating pancreatic cancer metastases using combined treatments including liposomal irinotecan and oxaliplatin
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
Gelmon et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
US20130338129A1 (en) Method of treating refractory cancer
ES2984592T3 (es) Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2
CN101330917A (zh) 固定比率的联合用药治疗实体瘤
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
KR20100042549A (ko) 병용 방법 및 조성물
KR20160017660A (ko) 병용 방법 및 조성물
HK1160032A (en) Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
HK1160032B (en) Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
Shepherd et al. Phase II trial of MTA (AlimtaTM) and cisplatin in patients with advanced Non-Small Cell Lung Cancer (NSCLC)
Matsuyama et al. The relationship between HER2/neu expression and drug resistance for non-small cell lung cancer
van Putten et al. Phase II study of docetaxel (DOC) and carboplatin (CP) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Koch et al. Gemcitabine: Clinical and economic impact in inoperable non-small cell lung cancer

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240905

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240905

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20251210